One study examined the expression status of HER3 in mCRC patients and concluded that there was a moderate correlation between HER3 expression in primary tumors and liver metastasis in CRC, and there was no difference in the expression of HER3 in synchronous and metachronous liver metastasis. This evidence concerns the gene ERBB3 and metastasis.